Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...
Artificial intelligence (AI)-powered tools are becoming increasingly common within clinical practice and medical education, and using AI in simulation as a pure learning tool and for assessment has been widely discussed. Targeted, efficient use of such tools has been shown...
5 October 2020
| Ronnie Mooney, Roderick Williams, Fiona Henriquez (Prof)
|
EYE - Cornea, EYE - General
The global increase in Acanthamoeba keratitis infections has emphasised the inefficiencies of current treatment and preventative methods, here researchers from the West of Scotland detail a promising new series of compounds that may stem the tide. News headlines detailing horror...
In 2017 the St John Ophthalmic Association (SOA) was established by ophthalmic practitioners across the world to support the St John of Jerusalem Eye Hospital Group. The purpose of the Association is to broaden the ophthalmic expertise available to St John and its staff.
We present the case of a 53-year-old lady who presented to the diabetes outpatient clinic at Kamuzu Central Hospital (KCH), Lilongwe, Malawi. She was diagnosed with type 2 diabetes mellitus six years ago, for which she takes metformin orally. She...
19 September 2025
| Zheng Yang Xu, Dilraj Sahota
|
EYE - Glaucoma
Hypertensive anterior uveitis can present a diagnostic challenge to clinicians working in emergency eye departments. While prompt initial control of intraocular pressure (IOP) and inflammation is essential, elucidating the underlying aetiology is critical for long-term visual outcomes. When there is...
The vast majority of medical students have positive attitudes towards the COVID-19 vaccine for themselves and patients, however, what about the small inevitable minority who resist it? Should they be prevented from attending clinical attachments in the NHS? It is...
An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...
1 June 2015
| Rita McLauchlan, D Armstrong, Konstantinos Balaskas, Sajjad Mahmood
|
EYE - Vitreo-Retinal
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...
Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...
1 October 2019
| Saqalain Kassamali, Liya Ayalew, Ben Parkin, Marcia Zondervan, Will Dean, Karinya Lewis, Fatima Kyari, Heiko Philippin, Sheila Marco, Faith Masila, Daniel Kiago, Helen Roberts, Josiah Onyango
|
EYE - Glaucoma, EYE - General
In order to enhance specialist skills, particularly for South Sudan, the Juba-Bournemouth VISION 2020 LINK has been offering week-long intensive ophthalmic specialist training for the last three years, in collaboration with the University of Nairobi, the College of Ophthalmology of...
The role of the optometrist has expanded in recent years as community eye care services have changed. With the limited scope of general ophthalmic services (GOS) regulations in most parts of the UK, the funding to support additional care has...